|
Compound class:
Synthetic organic
Comment: Losudesivir is the INN for an adenosine analogue that is intended as a coronavirus antiviral agent. The structure was obtained from WHO INN Proposed List 135 (July 2026). It represents an orally bioavailable RdRp inhibitor known by the codes SHEN26 and ATV014 that exhibits broad-spectrum activity against multiple coronaviruses [3-5]. Structurally, losudesivir is a cyclohexane carboxylate prodrug of the parent compound and active metabolite of remdesivir, GS-441524. Mechanistically RdRp inhibitors disrupt viral nucleic acid synthesis and thereby replication.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Bai J, Asakawa T, Yuan W, Lin Y, Ju H, Xu D, Yang M, Li S, Li G, Guo D et al.. (2025)
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Virol J, 22 (1): 16. [PMID:39863888] |
|
2. Sun C, Liu H, Ouyang Z, Ding J, Zhang Q, Ma H, Xu D, Zhang Q, Zhou R, Yang M et al.. (2024)
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects. Expert Opin Investig Drugs, 33 (5): 533-542. [PMID:38662639] |
|
3. Yang S, Li K, Zhou Q, Zhang X, Guo D. (2025)
Broad-Spectrum Antiviral Activity of the Orally Bioavailable Antiviral ATV014 Against Multiple Coronaviruses. MedComm (2020), 6 (5): e70186. [PMID:40242157] |
|
4. Zheng P, Li G, Chen Y, Li S, Yang S, Guo D, Zhou Q, Zhang X. (2025)
Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment. Bioorg Med Chem Lett, 124: 130243. [PMID:40250816] |
|
5. Zhou Q, Yang S, Cao L, Yang Y, Xu T, Chen Q, Lu H, Li Y, Guo D, Zhang X. (2023)
Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside. Signal Transduct Target Ther, 8 (1): 27. [PMID:36635259] |